What is HC Wainwright's Estimate for COYA Q1 Earnings?

Key Points

• HC Wainwright analyst R. Selvaraju estimates Coya will post Q1 2027 EPS of ($0.46) and reiterates a Buy rating with an $18 price target.
• HC Wainwright's updated 2027 outlook projects a FY2027 EPS of ($1.66), notably deeper than the market consensus of ($1.15), indicating larger expected losses.
• Coya's most recent quarter showed EPS of ($0.34) versus consensus ($0.08) despite revenue beating at $3.96 million, and the company continues to report negative margins and returns.

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Coya Therapeutics in a note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.66) EPS.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.26). The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Coya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital reaffirmed a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $15.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Coya Therapeutics Stock Performance

Shares of COYA opened at $4.22 on Tuesday. Coya Therapeutics has a fifty-two week low of $3.94 and a fifty-two week high of $7.75. The firm has a market cap of $99.00 million, a price-to-earnings ratio of -3.32 and a beta of 0.23. The firm has a 50 day moving average price of $4.68 and a 200-day moving average price of $5.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $192,000. Occudo Quantitative Strategies LP purchased a new position in Coya Therapeutics during the fourth quarter valued at $66,000. Millennium Management LLC purchased a new position in Coya Therapeutics during the fourth quarter valued at $121,000. 683 Capital Management LLC bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at $465,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Coya Therapeutics in the 4th quarter worth about $128,000. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics News Roundup

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and an $18 price target on COYA, representing a large upside from current levels; the firm cites pipeline potential and upcoming program catalysts as the rationale. Benzinga
• Positive Sentiment: A TipRanks summary of HC Wainwright’s coverage emphasizes Coya’s advancing Treg‑focused pipeline and near‑term catalysts (ALS and FTD) as supporting the Buy rating and long‑term upside thesis. Coya Therapeutics: Advancing Treg-Focused Pipeline...
• Neutral Sentiment: Reported short‑interest data for March show effectively zero shares on file and a 0.0 days‑to‑cover figure — an odd/ambiguous data point that neither clearly pressures nor supports the stock given the lack of meaningful short activity.
• Negative Sentiment: HC Wainwright’s updated 2027 forecasts show deeper quarterly and full‑year losses than the market consensus (FY2027 EPS forecast of -$1.66 vs. consensus -$1.15), which could concern investors focused on near‑term dilution and cash needs despite the Buy rating.
• Negative Sentiment: Recent company results (reported March 16) showed an EPS miss for the quarter (reported -$0.34 vs. -$0.08 expected) despite revenue beating estimates; continued quarterly losses and negative margins remain a risk to sentiment until clear clinical or commercial readouts reduce execution uncertainty.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.